LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

MRK

115.87

+0.54%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

MRK

115.87

+0.54%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

MRK

115.87

+0.54%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

MRK

115.87

+0.54%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

MRK

115.87

+0.54%↑

Начало・Списък с акции・Novartis AG

Novartis AG

Затворен

154.48 0.12

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

154.24

Максимум

155.63

Ключови измерители
By Trading Economics
Приходи	-1.5B 2.4B
Продажби	-1B 13B
P/E Средно за сектора	22.768 61.417
EPS	2.03
Дивидентна доходност	2.93
Марж на печалбата	18.064
Служители	75,267
EBITDA	-769M 5.1B

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+7.83% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	2.93% 2.40%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	25B 315B
Предишно отваряне	154.36
Предишно затваряне	154.48

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

N/A / 112.63 Подкрепа & съпротива

Novartis AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.03.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

20.02.2026 г., 05:06 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Exit Indian Arm With Stake Sale

4.02.2026 г., 11:38 ч. UTC

Печалби

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S. -- Update

4.02.2026 г., 06:40 ч. UTC

Печалби

Novartis Sales Rise Despite Generic Drug Competition in U.S.

28.10.2025 г., 12:38 ч. UTC

Печалби

Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead -- 2nd Update

28.10.2025 г., 10:23 ч. UTC

Печалби

Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead -- Update

28.10.2025 г., 07:14 ч. UTC

Печалби

Correction to Novartis Article

28.10.2025 г., 07:08 ч. UTC

Печалби

Novartis Posts Higher Net Profit as Key Drugs Lift Sales

6.02.2026 г., 12:35 ч. UTC

Печалби

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

4.02.2026 г., 08:04 ч. UTC

Пазарно говорене

Печалби

Novartis 2026 Guidance a Bit Soft on Earnings -- Market Talk

4.02.2026 г., 06:04 ч. UTC

Печалби

Novartis Expects 2026 Core Operating Profit to Decline Low Single-digit

4.02.2026 г., 06:04 ч. UTC

Печалби

Novartis Expects 2026 Net Sales to Grow Low Single-Digit

4.02.2026 г., 06:03 ч. UTC

Печалби

Novartis Proposes Dividend of CHF3.70 per share for 2026

4.02.2026 г., 06:02 ч. UTC

Печалби

Analysts Saw Novartis 2025 Core Operating Profit at $21.85B

4.02.2026 г., 06:02 ч. UTC

Печалби

Novartis 2025 Core Operating Profit $21.89B

4.02.2026 г., 06:01 ч. UTC

Печалби

Novartis 2025 Sales $54.53B

4.02.2026 г., 06:01 ч. UTC

Печалби

Analysts Saw Novartis 2025 Sales at $54.82B

4.02.2026 г., 06:00 ч. UTC

Печалби

Novartis AG 4Q Net Pft $2.4B

20.01.2026 г., 10:05 ч. UTC

Пазарно говорене

DAVOS: Novartis Can Weather Shifts in Tariff Landscape, CEO Says -- Market Talk

16.01.2026 г., 17:03 ч. UTC

Пазарно говорене

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

22.12.2025 г., 08:48 ч. UTC

Пазарно говорене

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

20.11.2025 г., 10:09 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Novartis to Continue to Look for Deals With High Bar, CEO Says -- Market Talk

20.11.2025 г., 08:51 ч. UTC

Пазарно говорене

Novartis's Recent Performance Adds Credibility to New Outlook -- Market Talk

20.11.2025 г., 08:41 ч. UTC

Пазарно говорене

Novartis's Targets Exceed Expectations, But Investors Might Stay Cautious -- Market Talk

28.10.2025 г., 13:53 ч. UTC

Придобивния, сливания и поглъщания

Novartis Completes Acquisition of Tourmaline Bio

28.10.2025 г., 11:02 ч. UTC

Печалби

Earnings Roundup Today: UnitedHealth, UPS, Novartis -- WSJ

28.10.2025 г., 09:46 ч. UTC

Пазарно говорене

Печалби

Novartis's Results, Guidance Suggest Analysts' Overconfidence -- Market Talk

28.10.2025 г., 08:59 ч. UTC

Горещи акции

Stocks to Watch Tuesday: Amazon, NextEra, UnitedHealth, Nvidia -- WSJ

28.10.2025 г., 06:52 ч. UTC

Печалби

Correct: Novartis 3Q Core Operating Profit $5.46B

28.10.2025 г., 06:08 ч. UTC

Печалби

Novartis 3Q EPS $2.04

Сравнение с други в отрасъла

Ценова промяна

Novartis AG Прогноза

Ценова цел

By TipRanks

7.83% нагоре

12-месечна прогноза

Среден 167 USD 7.83%

Висок 180 USD

Нисък 141 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Novartis AG през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Novartis AG през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 112.63Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.